The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
== Chemistry == Oxymorphone is commercially produced from thebaine, which is a minor constituent of the opium poppy (Papaver somniferum) but thebaine is found in greater abundance (3%) in the roots of the oriental poppy (Papaver orientale). German patents from the mid-1930s indicate that oxymorphone as well as hydromorphone, hydrocodone, oxycodone, and acetylmorphone can be prepared—without the need for hydrogen gas—from solutions of codeine, morphine, and dionine by refluxing an acidic aqueous solution, or the precursor drug dissolved in ethanol, in the presence of certain metals, namely palladium and platinum in fine powder or colloidal form or platinum black. Oxymorphone hydrochloride occurs as odourless white crystals or white to off-white powder. It darkens in colour with prolonged exposure to light. One gram of oxymorphone hydrochloride is soluble in 4 ml of water and it is sparingly soluble in alcohol and ether. It degrades upon contact with light. Oxymorphone can be acetylated like morphine, hydromorphone, and some other opioids. Mono-, di-, tri-, and tetra- esters of oxymorphone were developed in the 1930s but are not used in medicine at this time. Presumably other esters such as nicotinyl, benzoyl, formyl, or cinnamyl can be produced. The 2013 US DEA annual manufacturing quotas were 18 375 kilogrammes for conversion (a number of drugs can be made from oxymorphone, both painkillers and opioid antagonists like naloxone) and 6875 kg for direct manufacture of end-products.
== External links == H. E. Carter & Minor J. Coon: William Cumming Rose from National Academy of Sciences Daphne A. Roe (1981) William Cumming Rose: A biographical sketch Journal of Nutrition 111(8):1311–20. Noyes Laboratory at the University of Illinois, Urbana-Champaign from American Chemical Society National Historic Chemical Landmarks William C. Rose Papers, University of Illinois Archives https://loguepedia.com/william-rose-american-scientist/
=== Environmental factors === Environmental risk factors for addiction are the experiences of an individual during their lifetime that interact with the individual's genetic composition to increase or decrease their vulnerability to addiction. Several environmental factors have been implicated as risk factors for addiction, including various psychosocial stressors. The National Institute on Drug Abuse lists early aggressive behavior, lack of parental supervision, peer substance use, the availability of substances, and poverty as risk factors for substance use among children and adolescents. Adverse childhood experiences, as defined by the Adverse Childhood Experiences Study, show a graded dose–response association with later harm. A meta-analysis pooling more than 250,000 participants found that people reporting four or more such experiences were at increased risk of every health outcome examined, with the strongest associations for problematic drug use. Chronic childhood exposure to physical, emotional, or sexual abuse, physical or emotional neglect, witnessing violence in the household, or a parent being incarcerated or having a mental illness is associated with substance use disorder in adolescence and adulthood, and people in treatment for addiction report such experiences far more often than the general population. Impaired emotion regulation and reduced impulse control are among the proposed pathways, with substance use adopted as a way of coping, particularly during adolescence.
== History == Thiotepa and its synthesis were patented in 1952 by the American Cyanamid company. It was made for use in the textile industry and in the production process of plastics. However, thiotepa entered human trials in 1953 and was found to be effective against acute myeloid leukemia, chronic myelogenous leukemia, and Hodgkin's lymphoma. The first clinical trial noted a "reasonable margin for safety" between the apparent dose and undesired bone marrow suppression In January 2007, the European Medicines Agency (EMA) designated thiotepa as an orphan drug. In April 2007, the United States FDA designated thiotepa as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In June 2024, the FDA approved a ready-to-dilute liquid formulation of thiotepa to treat breast and ovarian cancer.
Sources: en.wikipedia.org
==== Molecular fingerprints ==== A molecular fingerprint is a binary vector, where each position corresponds to a specific molecular property. In this representation, a given position X may encode the presence or absence of a particular substructure, with '1' indicating presence and '0' indicating absence. Various types of molecular fingerprints exist, including PubChem CACTVS fingerprints, Klekota-Roth fingerprints, MACCS fingerprints, and Extended-Connectivity Fingerprints (ECFP). A molecular fingerprint can be deterministically computed from a given molecular structure. Different molecular structures may yield the same molecular fingerprint.
==== Malaysia ==== Most Malaysian think tanks are related either to the government or a political party. Historically they focused on defense, politics and policy. However, in recent years, think tanks that focus on international trade, economics, and social sciences have also been founded. Notable think tanks in Malaysia include:
A dog is of a very hot nature: he should therefore never be without clean water by him, that he may drink when he is thirsty. In regard to their food, carrion is by no means proper for them. It must hurt their sense of smelling, on which the excellence of these dogs greatly depends. Barley meal, the dross of wheatflour, or both mixed together, with broth or skim'd milk, is very proper food. For change, a small quantity of greaves from which the tallow is pressed by the chandlers, mixed with their flour; or sheep's feet well baked or boiled, are a very good diet, and when you indulge them with flesh it should always be boiled. In the season of hunting your dogs, it is proper to feed them in the evening before, and give them nothing in the morning you take them out, except a little milk. If you stop for your own refreshment in the day, you should also refresh your dogs with a little milk and bread. In 1833, The Complete Farrier gave similar but far more extensive advice on feeding dogs:
New Zealand has a long history of sporting contact with South Africa, especially through rugby union. Until the 1970s this resulted in discrimination against Māori players, since the apartheid political system in South Africa for most of the twentieth century did not allow people of different races to play sport together, and therefore South African officials requested that Māori players not be included in sides which toured their country. Despite some of New Zealand's best players being Māori, this was agreed to, and Māori were excluded from tours of South Africa. Some Māori always objected to this, but it did not become a major issue until 1960, when there were several public protests at Māori exclusion from that year's tour. The protest group Halt All Racist Tours was formed in 1969. Although this was an issue in which Māori were central, and Māori were involved in the protests, the anti-tour movement was dominated by Pākehā (white New Zealanders). In 1973 a proposed Springbok (South African rugby team) tour of New Zealand was cancelled. In 1976 the South African government relented and allowed a mixed-race All Black team to tour South Africa. However, by this time international opinion had turned against any sporting contact with South Africa, and New Zealand faced significant international pressure to cut ties. Despite this, in 1981 the Springboks toured New Zealand, sparking mass protests and civil disobedience.
Southern blotting A molecular biology method used to detect a specific sequence in DNA samples. The method combines separation of DNA fragments by gel electrophoresis, transfer of the DNA to a synthetic membrane, and subsequent identification of target fragments with radio-labeled or fluorescent hybridization probes. Compare northern blotting, western blotting, and eastern blotting.
Sources: en.wikipedia.org
=== United Cup === Zverev has started his season every year since 2023 by participating in the United Cup. In 2023, Zverev and Team Germany were placed in Group C alongside the Czech Republic and the USA. Against the Czech Republic, he lost to Jiří Lehečka. The Czech Republic won the tie over Germany 3–2. Against the US, he lost to Taylor Fritz. The USA beat Germany 5–0. Germany failed to qualify for the knockout round and ended third in Group C. In 2024, Zverev returned to the United Cup in Sydney, Australia for the second consecutive year, leading Team Germany alongside Angelique Kerber. He won both of his singles matches in the round-robin stage, defeating Lorenzo Sonego of Italy and Adrian Mannarino of France both in three sets. He played both mixed doubles matches in both ties with Angelique Kerber, partnering for the first time since 2019, and won against Team Italy but not Team France. Despite this, Team Germany managed to qualify as the best runner-up team from all countries participating in Sydney, advancing to the quarterfinals against Greece. There, Zverev decisively won his singles match against Stefanos Tsitsipas and his mixed doubles match, partnering with doubles specialist Laura Siegemund, against Maria Sakkari and Petros Tsitsipas. In the semifinal tie against Australia, Zverev was defeated by Alex de Minaur in three sets, allowing the Australian to crack the top 10 after previously making top 10 wins against Taylor Fritz and Novak Djokovic earlier that week.
=== Neurotoxicity === Neurotoxic effects have been observed in experimental studies linking the accumulation of BCAA and BCKA to the neuropathology seen in individuals with MSUD. Recent review articles have expanded on the neurotoxicity associated with MSUD, highlighting its contribution to changes in cellular bioenergetics (via disruption of the citric acid cycle in mitochondria), oxidative stress, and pro-inflammatory states. Changes have been observed in various markers related to each respective state. For cellular bioenergetics, changes include lactate levels, creatine levels, NAD+/NADH ratio (nicotinamide adenine dinucleotide), ATP (adenosine triphosphate) and pyruvate concentrations, mitochondrial complex activity, and CK (creatine kinase) activity. In oxidative stress, changes are seen in GSH (glutathione), MDA (malondialdehyde), TAR (total antioxidant response), nitric oxide, DNA oxidative damage levels, and the enzymatic activity of GPS (glutathione peroxidase), GR (glutathione reductase), CAT (catalase), and SOD (superoxide dismutase). For the pro-inflammatory state, biomarker changes are seen in IL-6 (interleukin-6), IL-10 (interleukin-10), IL-1beta (interleukin-1 beta), TNF-gamma (tumor necrosis factor-gamma), TNF-alpha (tumor necrosis factor-alpha), sICAM-1 (soluble intercellular adhesion molecule-1), sVCAM-1 (soluble vascular cell adhesion molecule-1), and cathepsin levels. These neurotoxic changes have been linked to the activation of neuronal apoptotic pathways, leading to cell death and morphological changes in the brain.
== Types of cells == Macrophages: Supported by a network of connective tissue. Understood as the Reticuloendothelial System, the RES allows microglial differential in the CNS, pulmonary alveolar macrophages, tissue histiocytes, Kupffler Hepatic macrophages, Glomerular Mesangial Proliferation and unnamed Splenic expression of wandering macrophages. Sharing of iron storage remains an essential mystery. Lymphocytes: These are cells responsible for immune responses that circulate in the blood. Normally, only small numbers are found in the CTs throughout the body. The number increases dramatically at certain sites of tissue inflammation. They are also very numerous in the lamina propria of the respiratory and gastrointestinal tracts, where they are involved in immunosurveillance. The lamina propria is a layer of loose CT lying immediately beneath the epithelium. Plasma cells: Plasma cells are derived from B-lymphocytes and produce antibodies against a specific antigen. They have a limited migratory ability and a short life. Neutrophils: Neutrophils are white blood cells that act as phagocytes in the early stages of acute inflammation. Eosinophils: Eosinophils are white blood cells that are found in the lamina propria of the GI tract, and at sites of allergic reaction and parasitic infection. Basophils: Basophils are white blood cells that are similar to mast cells in having vasoactive agents released in response to an allergen. Monocytes: Monocytes are white blood cells that will give rise to all the phagocytes of the mononuclear phagocytic system (see Ross et al., pg.
Symptoms relating to ischemia Changes on an electrocardiogram (ECG), such as ST segment changes, new left bundle branch block, or pathologic Q waves Changes in the motion of the heart wall on imaging Demonstration of a thrombus on angiogram or at autopsy.
Chanterelles are common in Eurasia, North America (including Central America) and Africa. In the American Pacific Northwest, they can be found from July to November. They tend to grow in clusters in mossy coniferous forests, but are also often found in mountainous birch forests and among grasses and low-growing herbs. In central Europe, the golden chanterelle is often found in beech forests among similar species and forms. In the UK, they may be found from July through December.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.